Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Rein Therapeutics published positive first-in-human clinical data for LTI-03 in Nature Communications, demonstrating safety and reduced markers of lung scarring in IPF patients. The randomized study showed significant reductions in key inflammatory markers at both 5 mg and 10 mg doses over 14 days. At the higher 10 mg dose, LTI-03 reduced a direct marker of collagen deposition and showed SP-D reduction levels comparable to approved IPF therapies after twelve weeks of treatment. The study also suggested the drug may help preserve the lung's repair cells.
Key figures
- Drug Name
- LTI-03
- Phase Of Trial
- Phase 1
- Doses tested mg
- [5,10]
- Study duration days
- 14
- Phase 2 expected enrollment
- 120
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.